Hanny Al-Samkari

Nov 13, 2024 | onlinelibrary.wiley.com | Hanny Al-Samkari

Conflicts of Interest Dr Al-Samkari reports research funding to his institution (Agios, Sobi, Novartis, Vaderis, Amgen) and consultancy (Agios, Sobi, Alnylam, Novartis, Alpine, argenx, Amgen, Pharmacosmos). References 1, , , et al., “The Variable Manifestations of Disease in Pyruvate Kinase Deficiency and Their Management,” Haematologica 105, no. 9 (2020): 2229–2239.

Nov 3, 2024 | onlinelibrary.wiley.com | Hanny Al-Samkari |Donald C. Moore

In their paper, Galamaga and colleagues present a case series of six patients with persistent chemotherapy-induced thrombocytopenia (CIT) who were successfully treated with the oral thrombopoietin receptor agonist (TPO-RA) avatrombopag.1 All six patients appeared to benefit from avatrombopag support, with robust improvements in platelet counts facilitating continued chemotherapy with minimal chemotherapy dose reductions and/or treatment delays.

Aug 6, 2024 | onlinelibrary.wiley.com | Hanny Al-Samkari

1 INTRODUCTION Immune thrombocytopenia (ITP) is an autoimmune platelet disorder resulting in bleeding and constitutional symptoms that afflicts approximately one in 20 000 people worldwide.1 Although initially believed to occur due to the production of glycoprotein-specific platelet autoantibodies leading to destruction of platelets in the reticuloendothelial system, the pathogenesis of ITP is now recognized to be more complex, involving numerous other aspects of the immune system including...

Mar 18, 2024 | onlinelibrary.wiley.com | Alessandro Casini |Hemostasis Geneva Hospitals |Hanny Al-Samkari |Catherine Hayward

CONFLICT OF INTEREST STATEMENT A.C. reports fees for consultancy, grants and fees for travel paid to his institution from Octapharma, Sobi, LFB, Takeda, and Novo Nordisk. HAS reports consultancy (Agios, Amgen, Forma, Sobi, argenx, Pharmacosmos, Novartis, Moderna) and Research Funding (Agios, Sobi, Amgen, Vaderis, Novartis).

Aug 22, 2023 | onlinelibrary.wiley.com | Hanny Al-Samkari

In this issue of JIM, Dupuis-Girod et al. present the results of a French phase 2, randomized, placebo-controlled trial of systemic bevacizumab to treat bleeding in 24 patients with hereditary hemorrhagic telangiectasia (HHT) [1], the second most common hereditary bleeding disorder. HHT—a neglected [2] and not-so-uncommon bleeding disorder (afflicting 1 in 5000 persons, or 1.4 million people worldwide)—presently lacks any US FDA- or EMA-approved therapies [3].